AstraZeneca Stock Based Compensation To Revenue from 2010 to 2024

AZN Stock  USD 75.17  0.14  0.19%   
AstraZeneca PLC Stock Based Compensation To Revenue yearly trend continues to be very stable with very little volatility. Stock Based Compensation To Revenue is likely to drop to 0.01. Stock Based Compensation To Revenue is a metric that compares the total value of stock-based compensation granted by AstraZeneca PLC ADR to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. View All Fundamentals
 
Stock Based Compensation To Revenue  
First Reported
2010-12-31
Previous Quarter
0.0126
Current Value
0.0103
Quarterly Volatility
0.00172208
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 B, Interest Expense of 1.7 B or Total Revenue of 24.2 B, as well as many exotic indicators such as Price To Sales Ratio of 2.62, Dividend Yield of 0.0285 or PTB Ratio of 9.53. AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
  
This module can also supplement AstraZeneca PLC's financial leverage analysis and stock options assessment as well as various AstraZeneca PLC Technical models . Check out the analysis of AstraZeneca PLC Correlation against competitors.

Latest AstraZeneca PLC's Stock Based Compensation To Revenue Growth Pattern

Below is the plot of the Stock Based Compensation To Revenue of AstraZeneca PLC ADR over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. AstraZeneca PLC's Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AstraZeneca PLC's overall financial position and show how it may be relating to other accounts over time.
Stock Based Compensation To Revenue10 Years Trend
Slightly volatile
   Stock Based Compensation To Revenue   
       Timeline  

AstraZeneca Stock Based Compensation To Revenue Regression Statistics

Arithmetic Mean0.01
Geometric Mean0.01
Coefficient Of Variation15.20
Mean Deviation0
Median0.01
Standard Deviation0
Sample Variance0.00000297
Range0.0061
R-Value0.45
Mean Square Error0.00000254
R-Squared0.21
Significance0.09
Slope0.0002
Total Sum of Squares0.000042

AstraZeneca Stock Based Compensation To Revenue History

2024 0.0103
2023 0.0126
2022 0.014
2021 0.0164
2020 0.0104

About AstraZeneca PLC Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include AstraZeneca PLC income statement, its balance sheet, and the statement of cash flows. AstraZeneca PLC investors use historical funamental indicators, such as AstraZeneca PLC's Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although AstraZeneca PLC investors may use each financial statement separately, they are all related. The changes in AstraZeneca PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AstraZeneca PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on AstraZeneca PLC Financial Statements. Understanding these patterns can help to make the right decision on long term investment in AstraZeneca PLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Stock Based Compensation To Revenue 0.01  0.01 

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving together with AstraZeneca Stock

  0.63CGC Canopy Growth Corp Financial Report 27th of June 2024 PairCorr

Moving against AstraZeneca Stock

  0.68INTC Intel Financial Report 25th of July 2024 PairCorr
  0.56MCD McDonalds Financial Report 25th of July 2024 PairCorr
  0.49PFE Pfizer Inc Earnings Call This WeekPairCorr
  0.41HD Home Depot Financial Report 21st of May 2024 PairCorr
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:
Check out the analysis of AstraZeneca PLC Correlation against competitors.
Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Complementary Tools for AstraZeneca Stock analysis

When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Stocks Directory
Find actively traded stocks across global markets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.207
Dividend Share
2.9
Earnings Share
2.02
Revenue Per Share
2.5512
Quarterly Revenue Growth
0.165
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.